Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
B
288330
vs
K
KOSPI 200
Over the past 12 months, Bridge Biotherapeutics Inc has underperformed KOSPI 200, delivering a return of -73% compared to KOSPI 200's +52% growth.
Stocks Performance
288330 vs KOSPI 200
Performance Gap
288330 vs KOSPI 200
Performance By Year
288330 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Bridge Biotherapeutics Inc
Glance View
Bridge Biotherapeutics is a South Korean drug developer that creates experimental medicines, rather than selling finished pharmaceuticals. Its work centers on discovering and testing new treatments for diseases such as cancer, fibrotic lung disease, and inflammatory conditions. The company’s main job is to move drug candidates through lab work and clinical trials until they can be licensed or approved for sale. Because it does not rely on a big portfolio of marketed drugs, Bridge Biotherapeutics makes money mainly through research collaborations, licensing deals, and payments tied to its development programs. Its customers are usually pharmaceutical partners, research collaborators, and, if a drug is approved, doctors and patients who use the finished treatment through the healthcare system. What makes its business model different is that it sits early in the drug value chain. It takes scientific risk up front by building and testing new molecules, then often seeks partners with larger commercial reach to help fund later-stage development and sales. That gives it a pipeline-driven business that depends more on scientific progress and deal-making than on direct product sales.